News Website

Endometrial Cancer - Pipeline Insight, 2025: Immunotherapy - openPR.com

Endometrial Cancer - Pipeline Insight, 2025: Immunotherapy openPR.com

Published: June 30, 2025, 6:49 p.m.

Read Full Article

Changes in the M1/M2 ratio due to andrographolide therapy for deep endometriosis: An experimental study using a BALB/C endometriosis model.

Andrographolide is a compound that serves as an anti-inflammatory agent. M2 macrophages promote the disease, while M1 macrophages inhibit endometriosis progression.

Published: June 30, 2025, midnight

Read Full Article

Andrographolide Endometriosis M1/M2 ratio Peritoneal Fluid

Molecular profiling reduces need for radiotherapy in endometrial cancer - Contemporary OB/GYN

Molecular profiling reduces need for radiotherapy in endometrial cancer Contemporary OB/GYN

Published: June 24, 2025, 5:47 p.m.

Read Full Article

Progyny Adds Pelvic Floor Therapy, Continuing to Close Gaps in Care Across Women’s Health - TradingView

Progyny Adds Pelvic Floor Therapy, Continuing to Close Gaps in Care Across Women’s Health TradingView

Published: June 24, 2025, 1:10 p.m.

Read Full Article

Women gain strength, mobility, confidence by working with physical therapy team at The Fit Pelvis - Community Impact

Women gain strength, mobility, confidence by working with physical therapy team at The Fit Pelvis Community Impact

Published: June 20, 2025, 3 p.m.

Read Full Article

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer - BioSpace

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer BioSpace

Published: June 9, 2025, 12:43 p.m.

Read Full Article

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer | AZN Stock News - GuruFocus

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer | AZN Stock News GuruFocus

Published: June 9, 2025, 12:18 p.m.

Read Full Article

Adding immunotherapy to standard chemotherapy extends quality of life for patients with advanced endometrial cancer - Medical Xpress

Adding immunotherapy to standard chemotherapy extends quality of life for patients with advanced endometrial cancer Medical Xpress

Published: June 2, 2025, 6:20 p.m.

Read Full Article

Adding immunotherapy to standard chemotherapy extends quality of life for patients with advanced endometrial cancer | Newswise - Newswise

Adding immunotherapy to standard chemotherapy extends quality of life for patients with advanced endometrial cancer | Newswise Newswise

Published: June 2, 2025, 2:25 p.m.

Read Full Article

Weekly Wellness: Pelvic Health and Pelvic Floor Therapy - FOX 17 West Michigan News

Weekly Wellness: Pelvic Health and Pelvic Floor Therapy FOX 17 West Michigan News

Published: May 28, 2025, 3:11 p.m.

Read Full Article

Latest Articles

Endometrial Cancer - Pipeline Insight, 2025: Immunotherapy - openPR.com

Changes in the M1/M2 ratio due to andrographolide therapy for deep endometriosis: An experimental study using a BALB/C endometriosis model.

Molecular profiling reduces need for radiotherapy in endometrial cancer - Contemporary OB/GYN

Progyny Adds Pelvic Floor Therapy, Continuing to Close Gaps in Care Across Women’s Health - TradingView

Women gain strength, mobility, confidence by working with physical therapy team at The Fit Pelvis - Community Impact

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer - BioSpace

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer | AZN Stock News - GuruFocus

Adding immunotherapy to standard chemotherapy extends quality of life for patients with advanced endometrial cancer - Medical Xpress

Adding immunotherapy to standard chemotherapy extends quality of life for patients with advanced endometrial cancer | Newswise - Newswise

Weekly Wellness: Pelvic Health and Pelvic Floor Therapy - FOX 17 West Michigan News

Subscribe to Our Newsletter